antisclerostin

However, in OA the findings in preclinical studies using antisclerostin therapy have been disappointing, as genetic absence of sclerostin or antisclerostin therapy with monoclonal antibody had no impact on articular cartilage remodeling in animals with age-dependent OA or post-traumatic OA, respectively [ 32 ].

2015 June 12, Ioanna Papathanasiou et al., “DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter”, in Arthritis Research & Therapy, volume 17, →DOI